Trends in Glioma Treatment Show Increased Survival Rates

Share this content:

the Neurology Advisor take:

Between 1999 and 2010, survival rates for grade I, II, and III astrocytoma improved, highlighting the clinical practices that impact the clinical course of the glioma subtype.

Xuezhi Dong, MD, of the University of California, and colleagues used the Surveillance, Epidemiology, and End Results (SEER) database to identify 2,497 grade I, 4,113 grade II, and 2,755 grade III cases of astrocytomas from 1999 through 2010.

During the study period, overall survival of grade I astrocytoma remained the same, however improved survival was seen in patients with grades II and III astrocytoma (Tarone-Ware P < .05). Median survival for grade II patients increased from 44 to 57 months and from 15 to 24 months for grade III patients. After adjusting for variables including age, ethnicity, sex, marital status, tumor size and location, extent of surgical resection (EOR), and radiation treatment (RT) status, survival differences remained significant.

The researchers observed little change in clinical practice in EOR for both grade II and grade III astrocytomas, however there was a decrease in use of radiation treatment for grade II astrocytomas after 2005.

brain mri
Trends in Glioma Treatment Show Increased Survival Rates

The survival trends and the patterns of clinical practice pertaining to radiation therapy and surgical resection for WHO grade I, II, and III astrocytoma patients remain poorly characterized.

Using the Surveillance, Epidemiology and End Results (SEER) database, we identified 2497 grade I, 4113 grade II, and 2755 grade III astrocytomas during the period of 1999–2010. Time-trend analyses were performed for overall survival, radiation treatment (RT), and the extent of surgical resection (EOR).

While overall survival of grade I astrocytoma patients remained unchanged during the study period, we observed improved overall survival for grade II and III astrocytoma patients (Tarone-Ware P < .05).

You must be a registered member of Neurology Advisor to post a comment.

Sign Up for Free e-newsletters

CME Focus